Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|January 28, 2025

Leveraging Telehealth and Collaboration for Rural and Community Care Expansion

Author(s)Jeffrey V. Matous, MD

Jeffrey V. Matous, MD, discusses how primary barriers to the widespread use of bispecific antibody therapies in community practices can be addressed through innovative care models, while reflecting on key insights from ASH 2024 abstracts that could guide broader adoption of these therapies in community settings.

Episodes in this series

EP. 1 Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies

EP. 1 Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies

EP. 2 Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management

EP. 2 Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management

EP. 3 Proactive CRS Management: The Role of Tocilizumab and Beyond

EP. 3 Proactive CRS Management: The Role of Tocilizumab and Beyond

EP. 4 Expanding Bispecific Therapies to Community Settings: Challenges and Innovations

EP. 4 Expanding Bispecific Therapies to Community Settings: Challenges and Innovations

EP. 5 Leveraging Telehealth and Collaboration for Rural and Community Care Expansion

EP. 5 Leveraging Telehealth and Collaboration for Rural and Community Care Expansion

EP. 6 Streamlining Transitions Between Academic and Community Centers

EP. 6 Streamlining Transitions Between Academic and Community Centers

EP. 7 Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery

EP. 7 Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery

Video content above is prompted by the following:

What are the primary barriers preventing widespread use of bispecific antibody therapies in community practices, and what innovative solutions or models of care could help address these challenges?
Several ASH 2024 abstracts highlighted community center experiences with bispecific antibody therapies. What insights from these studies stand out to you, and how can they guide broader adoption of these therapies in the community setting?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Swarup Kumar, MD

Bringing Cutting-Edge MM Therapy to Every Patient: Swarup Kumar, MD

ByMaggie L. Shaw,Swarup Kumar, MD

June 30th 2026

Screening, Risk Stratification, and the Multidisciplinary Care Model for MASH

ByNadege Gunn, MD

June 30th 2026

Experts featured in this series.

Beyond Brand vs. Generic: What Really Drives Treatment Decisions After Repeated Failures

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 30th 2026 | Updated: June 16th 2026

MASH in Focus: How Patient Awareness, Clinical Empowerment, and Research Have Transformed the Field

ByNadege Gunn, MD

June 30th 2026

Experts featured in this series.

When Treatment Isn't Working: Defining Failure and Charting the Next Steps in Psychiatric Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 30th 2026 | Updated: June 16th 2026

Trending on AJMC

COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV

New Bill Would Cap Traditional Medicare Out-of-Pocket Costs at $5000

Topical Delgocitinib Improves Chronic Hand Eczema Outcomes Across All Trial Timepoints

Community Oncology Must Adapt for CAR T, Bispecific Multiple Myeloma Care: Mohit Narang, MD

COA Offers Playbook to Help Community Oncology Practices Navigate AI Partnerships